Results 241 to 250 of about 564,228 (347)

Assessing the Health Impacts of Heated Tobacco Products Compared to Traditional Tobacco Use: A Systematic Review of Current Evidence. [PDF]

Cureus
Ambildhok KA, Asawa K, Garcha V.
europepmc   +1 more source

Cerebral Cortical Vasodilation via Nicotinic Receptors by Heated Tobacco Product Aerosol Extract in Rats

Sae Uchida, Jura Moriya, Daichi Morihara, Mayura Shimura, Fusako Kagitani   +4 more
openalex   +1 more source

Sustainability in Analytical Chemistry Illustrated by Pharmaceutical Nitrosamine Testing

ELECTROPHORESIS, EarlyView.
ABSTRACT Following the valsartan scandal in 2018, the testing of drug substances and drug products for N‐nitrosamines has become a critical and mandatory quality control measure. The European Pharmacopoeia chapter 2.5.42 currently describes three analytical methods for this purpose: HPLC–MS/MS, GC–MS, and GC–MS/MS.
Felix Bredendiek, Sebastian Schmidtsdorff, Maria Kristina Parr   +2 more
wiley   +1 more source

Non-invasive exposure biomarkers of tobacco smoke exposure in smokers of classic cigarettes and users of e-cigarettes and heated tobacco products. [PDF]

Front Mol Biosci
Jończyk K, Kicman A, Michalska-Falkowska A, Śniadach J, Waszkiewicz N.   +4 more
europepmc   +1 more source

Minimum Age of Sale for Tobacco Products and Electronic Cigarettes: Ethical Acceptability of US “Tobacco 21 Laws”

, 2017
Stephanie R. Morain, Janet Malek
openalex   +2 more sources

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Perceptions of prevention and cessation ads among US youth who use multiple tobacco products: A qualitative study. [PDF]

Nicotine Tob Res
Clark SA, Patterson SL, Duguid I, Noar SM, Lazard AJ, Thrasher JF, Goldstein AO, Kowitt SD.   +7 more
europepmc   +1 more source

Methods of cessation of traditional and novel tobacco and nicotine product use: a systematic review to support nicotine-related prevention strategies.

Znotiņa, Inga, Vanadzins, Ivars, Straume, Ilze, Paegle, Diana Inga, Samel-Kowalik, Piotr, Miller, Natalia   +5 more
openalex   +1 more source

COVID-19 Outcome and Tobacco Product Use: Case-Control and Retrospective Cohort Studies Using Nationwide Samples [PDF]

Seo Young Kang, Ye‐Jee Kim, Hong‐Jun Cho   +2 more
openalex   +1 more source

Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study (ELUCID)

Epilepsia Open, EarlyView.
Abstract Objective Late‐onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10%–25% of individuals with LoUE develop dementia within 3–4 years following their first seizure.
Alice D. Lam, Emily L. Johnson, Rani A. Sarkis, Leah J. Blank, Tyler E. Gaston, Mouhsin M. Shafi, Rodrigo Zepeda, Kyle R. Pellerin, Nathalie Jette, Douglas N. Greve, Lori B. Chibnik, Rebecca E. Amariglio, Gad A. Marshall, M. Brandon Westover   +13 more
wiley   +1 more source